Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In studies, Retatrutide has shown the potential to help patients lose up to 25% or more of their body weight, especially in those who have not seen optimal results from other treatments
Tirzepatide, a dual GLP-1 and GIP receptor agonist, activates an additional appetite and metabolism pathway that semaglutide doesn't target
The experiment was repeated three times and the results were statistically analyzed using one-way ANOVA method following Tukey post-hoc hypothesis test
Phase 3 monotherapy results A post-hoc analysis of the phase 3 data showed cagrilintide 2.4 mg monotherapy produced 11.8% average body weight reduction versus 2.3% for placebo over 68 weeks
Some have also reported mild stomach upset or diarrhea
Pearce, B.C., Parker, R.A., Deason, M.E., Qureshi, A.A., Wright, J.J., 1992
US$ 26.03
US$ 21.98
US$ 22.28
US$ 26.58
US$ 23.40
US$ 24.45
US$ 24.15
US$ 29.90
